Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Formosa Laboratories, Inc. specializes in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates, primarily serving the generic and specialty drug markets. With a strong presence in Taiwan and expanding operations in the U.S. and Europe, Formosa benefits from its cost-effective production capabilities and established relationships with major pharmaceutical companies.
Formosa generates revenue primarily through the sale of generic APIs and specialty pharmaceuticals, leveraging its competitive pricing and strong R&D capabilities to capture market share. The company also engages in contract manufacturing, providing additional revenue streams while optimizing its production capacity.
Regulatory approvals for new generic drugs
Changes in pricing regulations affecting generic pharmaceuticals
Market share shifts in key therapeutic areas
Cost fluctuations in raw materials
Regulatory changes impacting drug approval processes
Technological advancements in drug manufacturing that could disrupt existing processes
Intensifying competition from low-cost manufacturers in Asia
Potential loss of key contracts with large pharmaceutical companies
Moderate financial risk due to reliance on cash flow for ongoing investments
Potential liquidity risks if free cash flow declines significantly
moderate - The demand for pharmaceuticals tends to be less sensitive to economic cycles, but significant downturns can affect discretionary spending on healthcare.
Interest rates impact Formosa's financing costs, particularly as it invests in R&D and production capacity. Higher rates could compress margins if borrowing costs rise significantly.
minimal - Formosa's low debt-to-equity ratio (0.46) indicates limited reliance on credit markets for operations.
value - Investors may be drawn to Formosa's low price-to-book ratio (0.8x) and potential for recovery in margins.
moderate - The stock has experienced fluctuations, with a 1-year return of -24.8%, indicating some sensitivity to market conditions.
